[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547742":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":49,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"SamA Pharmaceutical Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Atock Dry Syrup","EXPERIMENTAL",null,[13],"Drug: Atock Dry Syrup with placebo patch",{"label":15,"type":16,"description":11,"interventionNames":17},"tulobuterol patch","ACTIVE_COMPARATOR",[18],"Drug: Tulobuterol patch with placebo dry syrup",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Atock Dry Syrup with placebo patch","Atock Dry syrup (TID) with placebo patch (QD)",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Tulobuterol patch with placebo dry syrup","Tulobuterol patch (QD) with placebo dry syrup (TID)",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Hyeon Jong Yang, MD","CONTACT","+82-2-709-9390","ilove902@hanmail.net",[36],{"facility":37,"status":38,"city":39,"state":11,"zip":11,"country":40,"countryCode":11,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Soonchunhyang University Seoul Hospital","RECRUITING","Seoul","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.9784,37.566,{"lat":45,"lon":44},[48],{"name":31,"role":32,"phone":11,"phoneExt":11,"email":11},{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100547742","phase-4-the-efficacy-and-safety-of-atock-dry-syrup-with-acute-bronchitis-patients-100547742",false,"NCT06411925","The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients","A Multi-center, Randomized, Double-blinded, Active-controlled, Non-inferiority, Phase 4 Trial to Evaluate the Efficacy and Safety of Atock Dry Syrup Sama With Acute Bronchitis Patients","Inclusion Criteria:\n\n1. Children aged ≥6 months to \\\u003C12 years old\n2. Total Bronchitis Severity Scale excluding sputum(BSSEs) ≥4\n3. Wheezing score ≥2\n4. Subjects who present symptoms of Acute Bronchitis within 48 hours from screening visit\n5. Subject with negative results in HbsAg or HCV Ab test within 6 months from screening visit\n\nExclusion Criteria:\n\n1. Subjects with chronic respiratory diseases (e.g., asthma, COPD) or severe respiratory diseases (e.g., pneumonia, cystic fibrosis, influenza, active tuberculosis)\n2. Subjects under treatment with corticosteroids, antibiotics medications\n3. Subjects with severe hepatic and renal impairment\n4. Subjects with a history of drug abuse\n5. Subject with positive results in HIV Ab test","ALL","6 Months","11 Years",{"count":62,"type":63},296,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","Clinical Study to Evaluate the Efficacy and Safety of Atock Dry Syrup with Acute bronchial Patients",[69],"Acute Bronchitis","2025-09-18",{"date":72,"type":73},"2025-09-23","ACTUAL",{"date":75,"type":73},"2023-11-10",{"date":77,"type":63},"2027-09",{"name":5,"class":6},1]